MedicaidPrior AuthLow impact
MAB2021111504
Pennsylvania Medicaid (DHS)·PA · Neurology, Pharmacy·Provider Bulletin
Effective date
Jan 3, 2022
We identified it
Jun 20, 2026
Summary
Pennsylvania Medicaid will no longer require prior authorization for Rilutek (riluzole) in the fee-for-service delivery system, effective January 3, 2022. This removes a previous authorization requirement that was implemented in 2014 due to appropriate utilization patterns and good safety profile.
Action Required
By January 3, 2022: Billing and pharmacy staff should update systems to remove prior authorization requirements for Rilutek (riluzole) for Pennsylvania Medicaid fee-for-service patients. Verify that billing software no longer flags this medication for prior auth. Note that managed care organizations may still have their own prior authorization requirements.